Down Syndrome and Alzheimer's Disease: A Scoping Review of Functional Performance and Fall Risk

Overview

Journal Alzheimers Dement (N Y)

Date 2023 May 25

PMID 37228575

Authors

Selena E Washington

Emily Cler

Cameron Lowery

Susan L Stark

Affiliations

Soon will be listed here.

Abstract

Introduction: Alzheimer's disease (AD) occurs in aging adults with Down syndrome (DS) at a higher prevalence and an earlier age than in typical aging adults. As with the general aging adult population, there is an urgent need to understand the preclinical and early phases of AD progression in the adult population with DS. The aim of this scoping review was to synthesize the current state of the evidence and identify gaps in the literature regarding functional activity performance and falls and their significance to disease staging (i.e., mild, moderate, and severe defined staging criteria) in relation to Alzheimer's disease and related dementias (ADRD) in adults with DS.

Methods: This scoping review included six electronic databases (e.g., PsycInfo, Academic Search Complete, CINAHL, COCHRANE Library, MEDLINE, and PubMed). Eligible studies included participants with DS ≥25 years of age, studies with functional measures and/or outcomes (e.g., activities of daily living, balance, gait, motor control, speech, behavior, and cognition; falls; and fall risks), and studies that investigated AD pathology and implications.

Results: Fourteen eligible studies were included and categorized through a thematic analysis into the following themes: (1) physical activity and motor coordination (PAMC), (2) cognition, (3) behavior, and (4) sleep. The studies indicated how functional activity performance and engagement may contribute to early identification of those at risk of cognitive decline and AD development and/or progression.

Discussion: There is a need to expand the research regarding ADRD pathology relative to functional outcomes in adults with DS. Functional measures related to disease staging and cognitive impairment are essential to understanding how AD progression is characterized within real-world settings. This scoping review identified the need for additional mixed-methods research to examine the use of assessment and intervention related to function and its detection of cognitive decline and AD progression.

Citing Articles

The association of dementia risk symptoms and functional activity in adults with Down syndrome.

Washington S, Bodde A, Helsel B, Bollinger R, Smith N, Ptomey L Alzheimers Dement (N Y). 2025; 10(4):e70007.

PMID: 39748853 PMC: 11694531. DOI: 10.1002/trc2.70007.

Partial loss of Sorting Nexin 27 resembles age- and Down syndrome-associated T cell dysfunctions.

Rodriguez-Rodriguez C, Gonzalez-Mancha N, Ochoa-Echeverria A, Liebana R, Merida I Immun Ageing. 2024; 21(1):2.

PMID: 38166948 PMC: 10759489. DOI: 10.1186/s12979-023-00402-3.

Down syndrome and Alzheimer's disease: A scoping review of functional performance and fall risk.

Washington S, Cler E, Lowery C, Stark S Alzheimers Dement (N Y). 2023; 9(2):e12393.

PMID: 37228575 PMC: 10203538. DOI: 10.1002/trc2.12393.

References

Handen B, Lott I, Christian B, Schupf N, OBryant S, Mapstone M . The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology. Alzheimers Dement (Amst). 2020; 12(1):e12065. PMC: 7396809. DOI: 10.1002/dad2.12065. View

Stark S, Roe C, Grant E, Hollingsworth H, Benzinger T, Fagan A . Preclinical Alzheimer disease and risk of falls. Neurology. 2013; 81(5):437-43. PMC: 3776538. DOI: 10.1212/WNL.0b013e31829d8599. View

Keleman A, Bollinger R, Wisch J, Grant E, Benzinger T, Ances B . Assessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease. OTJR (Thorofare N J). 2022; 42(4):277-285. PMC: 9665117. DOI: 10.1177/15394492221100701. View

McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N . A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017; 61(9):843-852. DOI: 10.1111/jir.12390. View

Pape S, Baksh R, Startin C, Hamburg S, Hithersay R, Strydom A . The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer's Disease in Down Syndrome. J Clin Med. 2021; 10(9). PMC: 8123639. DOI: 10.3390/jcm10091882. View

Dekker A, Sacco S, Carfi A, Benejam B, Vermeiren Y, Beugelsdijk G . The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. J Alzheimers Dis. 2018; 63(2):797-819. PMC: 5929348. DOI: 10.3233/JAD-170920. View

de Graaf G, Buckley F, Skotko B . Estimation of the number of people with Down syndrome in the United States. Genet Med. 2016; 19(4):439-447. DOI: 10.1038/gim.2016.127. View

Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Levac D . PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7):467-473. DOI: 10.7326/M18-0850. View

Dekker A, Ulgiati A, Groen H, Boxelaar V, Sacco S, Falquero S . The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation. J Alzheimers Dis. 2021; 81(4):1505-1527. PMC: 8293661. DOI: 10.3233/JAD-201427. View

10.

Krinsky-McHale S, Zigman W, Lee J, Schupf N, Pang D, Listwan T . Promising outcome measures of early Alzheimer's dementia in adults with Down syndrome. Alzheimers Dement (Amst). 2020; 12(1):e12044. PMC: 7335903. DOI: 10.1002/dad2.12044. View

11.

Tsou A, Bulova P, Capone G, Chicoine B, Gelaro B, Harville T . Medical Care of Adults With Down Syndrome: A Clinical Guideline. JAMA. 2020; 324(15):1543-1556. DOI: 10.1001/jama.2020.17024. View

12.

Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K . Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement. 2014; 11(6):700-9. PMC: 4817997. DOI: 10.1016/j.jalz.2014.10.007. View

13.

Snyder H, Bain L, Brickman A, Carrillo M, Esbensen A, Espinosa J . Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimers Dement. 2020; 16(7):1065-1077. PMC: 8865308. DOI: 10.1002/alz.12112. View

14.

Pelt K, Koehl L, Caban-Holt A, Anderson-Mooney A, Head E, Schmitt F . Feasibility of dual-task gait to estimate Alzheimer's related cognitive decline in Down syndrome. Alzheimers Dement (Amst). 2020; 12(1):e12092. PMC: 7447907. DOI: 10.1002/dad2.12092. View

15.

Alldred M, Martini A, Patterson D, Hendrix J, Granholm A . Aging with Down Syndrome-Where Are We Now and Where Are We Going?. J Clin Med. 2021; 10(20). PMC: 8539670. DOI: 10.3390/jcm10204687. View

16.

Lautarescu B, Holland A, Zaman S . The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies. Neuropsychol Rev. 2017; 27(1):31-45. PMC: 5359367. DOI: 10.1007/s11065-017-9341-9. View

17.

Baumer N, Becker M, Capone G, Egan K, Fortea J, Handen B . Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. J Neurodev Disord. 2022; 14(1):22. PMC: 8942061. DOI: 10.1186/s11689-022-09435-z. View

18.

Bollinger R, Keleman A, Thompson R, Westerhaus E, Fagan A, Benzinger T . Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. BMJ Open. 2021; 11(9):e050820. PMC: 8444237. DOI: 10.1136/bmjopen-2021-050820. View

19.

Aschenbrenner A, Baksh R, Benejam B, Beresford-Webb J, Coppus A, Fortea J . Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12184. PMC: 8088591. DOI: 10.1002/dad2.12184. View

20.

Oliver C, Adams D, Holland A, Brown S, Ball S, Dodd K . Acquired mild cognitive impairment in adults with Down syndrome: Age-related prevalence derived from single point assessment data normed by degree of intellectual disability. Int J Geriatr Psychiatry. 2022; 37(2). PMC: 9306607. DOI: 10.1002/gps.5674. View